Dalbavancin in acute bacterial skin infections: higher cost, higher readmission rates

  • PDF / 167,344 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 51 Downloads / 231 Views

DOWNLOAD

REPORT

73-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868

1

Data Loading...

Recommend Documents
Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients

168 14 448KB

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections

160 30 1MB

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections

149 98 294KB

Skin Manifestations of Systemic Bacterial Infections

164 25 882KB

Bacterial Infections

141 71 56MB

Mycobacterial Skin Infections

170 43 17MB

Prevention of Skin Infections

172 101 6MB

Dalbavancin

134 31 166KB

CML much higher treatment cost than other haematological cancers

147 85 163KB

Computations in Higher Types

182 38 7MB

Bacterial and Mycobacterial Infections

152 65 17MB

Diversity in Higher Education

252 2 13MB